Urology sits at a paradox in 2026: strong and growing patient demand on one side, sustained reimbursement pressure and administrative complexity on the other.
The specialty manages a disproportionate share of the country's aging population — patients over 65 use three times more urological services than the general population and account for nearly 65% of all urological care — while facing structural challenges that have been compounding for decades. The practices navigating this environment successfully are doing so deliberately. Here are the seven trends reshaping urology RCM in 2026.
1. The 2026 CPT Restructuring Requires Active Transition, Not Passive Updates
The deletion of CPT 55700 — the legacy prostate biopsy code that has been the workhorse of urology billing for years — is the most consequential coding change to hit the specialty in recent memory.
Effective January 1, 2026, CPT 55700 is invalid. Practices still submitting it receive automatic invalid-code rejections. The replacement code family (55707–55715) requires documentation specificity that the old code never demanded: the biopsy approach (transrectal vs. transperineal), whether the biopsy was systematic, targeted, or both, and the imaging guidance modality used.
The transition is two-sided: billing systems need updating and documentation templates need updating. Practices that updated one without the other are generating either invalid-code rejections (old billing templates) or audit-exposed claims (new codes without matching documentation).
Additional 2026 CPT changes affecting urology include new Category I codes for Aquablation, NanoKnife ablation, transurethral robotic-assisted resection, and transurethral anterior commissurotomy — all of which carry distinct documentation requirements that differ from the Category III T-codes they replace. Practices billing the new codes while still using documentation templates designed for the old codes are generating systematic claim quality issues.
2. The Efficiency Adjustment Creates Site-of-Service Strategy Decisions
The 2026 CMS Final Rule applied a -2.5% efficiency adjustment to work RVUs across nearly every service on the fee schedule. The net projected impact on urology is approximately 0% — but that average obscures a significant site-of-service differential: +5% for non-facility (office-based) services and -10% for facility-based services (hospital outpatient departments, ASCs, and inpatient).
For urology groups that perform procedures in both office-based and facility settings, this differential creates a real incentive to shift volume toward office-based delivery where clinically appropriate. Cystoscopies, biopsies, urodynamic studies, and certain minor surgical procedures performed in the office now generate meaningfully higher reimbursement than the same procedures at a hospital outpatient department.
Practices that haven't modeled this differential against their actual procedure mix and site distribution are leaving reimbursement optimization on the table. The groups building site-of-service strategy into their revenue modeling — rather than treating setting as a purely clinical decision — are protecting margins that their peers are quietly losing.
3. Ancillary Revenue Is Becoming the Margin Equation
For independent and mid-sized urology groups, ancillary services have become one of the most important financial levers available — and increasingly, the factor that determines which practices remain viable independently.
Urology's ancillary revenue sources — pathology labs, ASCs, lithotripsy services, radiation oncology programs, in-office dispensing — are among the most comprehensive of any specialty. PE-backed platforms actively target urology practices with owned ancillary services, which command significantly higher valuations.
But ancillary revenue is only valuable if it's captured correctly. The billing complexity of multi-service-line urology practices is substantial — each ancillary has its own CPT codes, supply codes, modifier logic, and compliance requirements. Groups that have invested in ancillary infrastructure but haven't invested in ancillary billing infrastructure are generating substantial uncollected revenue from services they're already delivering.
The practices maximizing ancillary revenue treat each service line as a distinct billing domain — with distinct workflows, distinct code validation logic, and distinct performance tracking — rather than routing everything through a shared general billing process.
4. Prior Authorization Hasn't Gotten Easier — And PSMA PET Is Adding to the Load
Independent urology practices report no decline in prior authorization workload despite multiple years of announced payer streamlining initiatives. In many cases, the load has increased as payers expand the list of procedures requiring authorization.
The newest and highest-dollar addition to urology's PA burden: PSMA PET imaging. Multiple FDA-approved PSMA PET agents are now in clinical use for prostate cancer staging and biochemical recurrence — including Pylarify (F-18 piflufolastat), Posluma (flotufolastat F 18), and two 68Ga-PSMA-11 agents. NCCN guidelines now explicitly recommend PSMA PET as a frontline imaging tool in several prostate cancer indications, but payer coverage policies are still catching up — and obtaining authorization requires navigating payer-specific criteria that vary significantly from plan to plan.
For urology oncology practices, PSMA PET authorization has become a significant workflow burden: high-cost studies, variable payer criteria, and prior authorization processes that require clinical documentation beyond what standard imaging requests involve.
5. Consolidation Is Accelerating — And Raising the Bar for Independent Groups
Urology consolidation has moved from local to national. Three PE-backed urology MSO platforms completed successful "second bites" in 2025, generating substantial returns for physician shareholders — validating the model and accelerating interest from remaining independent groups. GI Alliance's April 2025 acquisitions of Urology America and Potomac Urology marked a new phase of cross-specialty consolidation reaching into urology.
For the independent groups that remain, the competitive pressure is concrete. Consolidated platforms bring centralized RCM infrastructure, enterprise contract negotiation leverage, and economies of scale in ancillary services that independent practices struggle to match individually.
The independent groups building competitive positions in 2026 are doing so through operational infrastructure: automated billing workflows, data-driven contract management, and ancillary service models that deliver the financial performance of scale without requiring ownership consolidation.
6. The Workforce Shortage Is Creating Billing Fragility at the Worst Time
Over 60% of U.S. counties have no practicing urologist. About 41% of urology practices report difficulty filling urologist vacancies. And 58% of private practice urologists are 65 and older — meaning the retirements hitting the specialty over the next decade will be substantial.
The administrative side of this shortage is less visible but equally damaging. When practices are running at maximum clinical capacity with limited physician availability, billing quality suffers: documentation is rushed, coding is conservative, and follow-up on complex claims is deprioritized. The same staffing pressures affect the billing team: urology billing expertise is specialized, hard to recruit, and walks out the door every time a biller leaves.
The practices insulating themselves from this fragility aren't those with the deepest bench of billing staff. They're the ones that have automated the rules-based execution layer — so that coding accuracy and claim quality don't depend on any individual's knowledge or availability on any given day.
7. Long-Term Medicare Reimbursement Decline Demands Operational Precision
Inflation-adjusted Medicare reimbursement for urology's most common surgical procedures has declined steadily over the past 20 years — with prostatectomy, TURBT, and cystoscopy among the three most-affected codes. The primary driver is RVU reduction, driven largely by comparisons between open and robotic surgical techniques that effectively penalized efficiency improvements.
In that environment — where reimbursement per procedure is structurally declining — every dollar of preventable billing loss has compounding significance. A practice operating with a 5% denial rate and systematic undercoding in a declining-reimbursement environment is double-penalized: capturing less of a smaller pie.
The urology practices outperforming their peers in 2026 are those that have closed the gap between clinical revenue earned and clinical revenue collected. Not by changing payer relationships or growing case volume — but by ensuring that every service delivered is billed correctly, every claim that should be paid is paid, and every recoverable denial gets worked.
That precision, at scale, is what modern urology RCM looks like.
Want to see how Magical's AI employees are helping urology practices get ahead of these trends? Book a demo to walk through a workflow assessment for your practice.